secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merus N.V. (—)
CIK:        0001651311
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001193125-24-060033
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Merus enters $56M upfront collaboration with Gilead for trispecific antibody programs; potential $1.5B milestones
--------------------------------------------------------------------------------

- Gilead pays $56M upfront for rights to Merus' Triclonics platform; up to two more programs at $28M each.
- Total potential milestones up to ~$1.5B across three programs; tiered royalties mid-single to low double digits.
- Gilead purchases 452,527 shares at $55.2454/share (~$25M) in private placement; no transfer for set period.
- Merus may elect 50/50 profit-loss share for third program after first IND filing instead of milestones/royalties.
- Agreement covers at least two preclinical programs; Gilead has exclusive option per program to license and commercialize.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/0001193125-24-060033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/d815831d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-060033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer